-
Something wrong with this record ?
Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients
AM. Rulseh, J. Vymazal,
Language English Country United States
Document type Journal Article
Grant support
NV18-04-00457
Ministerstvo Zdravotnictví Ceské Republiky
DRO (NHH, 00023884) IG174301
Ministerstvo Zdravotnictví Ceské Republiky
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2009-07-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Antineoplastic Agents, Alkylating therapeutic use MeSH
- Chemoradiotherapy mortality MeSH
- Diffusion Magnetic Resonance Imaging methods MeSH
- Glioblastoma mortality pathology therapy MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Survival Rate MeSH
- Brain Neoplasms mortality pathology therapy MeSH
- Follow-Up Studies MeSH
- Image Processing, Computer-Assisted methods MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Retrospective Studies MeSH
- Temozolomide therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor, and methods to improve the early detection of disease progression and evaluate treatment response are highly desirable. We therefore explored changes in whole-brain apparent diffusion coefficient (ADC) values with respect to survival (progression-free [PFS], overall [OS]) in a cohort of GBM patients followed at regular intervals until disease progression. METHODS: A total of 43 subjects met inclusion criteria and were analyzed retrospectively. Histogram data were extracted from standardized whole-brain ADC maps including skewness, kurtosis, entropy, median, mode, 15th percentile (p15) and 85th percentile (p85) values, and linear regression slopes (metrics versus time) were fitted. Regression slope directionality (positive/negative) was subjected to univariate Cox regression. The final model was determined by aLASSO on metrics above threshold. RESULTS: Skewness, kurtosis, median, p15 and p85 were all below threshold for both PFS and OS and were analyzed further. Median regression slope directionality best modeled PFS (p = 0.001; HR 3.3; 95% CI 1.6-6.7), while p85 was selected for OS (p = 0.002; HR 0.29; 95% CI 0.13-0.64). CONCLUSIONS: Our data show tantalizing potential in the use of whole-brain ADC measurements in the follow up of GBM patients, specifically serial median ADC values which correlated with PFS, and serial p85 values which correlated with OS. Whole-brain ADC measurements are fast and easy to perform, and free of ROI-placement bias.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023289
- 003
- CZ-PrNML
- 005
- 20201214125648.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11060-019-03357-y $2 doi
- 035 __
- $a (PubMed)31797235
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rulseh, Aaron Michael $u Department of Radiology, Na Homolce Hospital, Roentgenova 2, 150 30, Prague 5, Czech Republic. aarulseh@gmail.com.
- 245 10
- $a Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients / $c AM. Rulseh, J. Vymazal,
- 520 9_
- $a INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor, and methods to improve the early detection of disease progression and evaluate treatment response are highly desirable. We therefore explored changes in whole-brain apparent diffusion coefficient (ADC) values with respect to survival (progression-free [PFS], overall [OS]) in a cohort of GBM patients followed at regular intervals until disease progression. METHODS: A total of 43 subjects met inclusion criteria and were analyzed retrospectively. Histogram data were extracted from standardized whole-brain ADC maps including skewness, kurtosis, entropy, median, mode, 15th percentile (p15) and 85th percentile (p85) values, and linear regression slopes (metrics versus time) were fitted. Regression slope directionality (positive/negative) was subjected to univariate Cox regression. The final model was determined by aLASSO on metrics above threshold. RESULTS: Skewness, kurtosis, median, p15 and p85 were all below threshold for both PFS and OS and were analyzed further. Median regression slope directionality best modeled PFS (p = 0.001; HR 3.3; 95% CI 1.6-6.7), while p85 was selected for OS (p = 0.002; HR 0.29; 95% CI 0.13-0.64). CONCLUSIONS: Our data show tantalizing potential in the use of whole-brain ADC measurements in the follow up of GBM patients, specifically serial median ADC values which correlated with PFS, and serial p85 values which correlated with OS. Whole-brain ADC measurements are fast and easy to perform, and free of ROI-placement bias.
- 650 _2
- $a alkylační protinádorové látky $x terapeutické užití $7 D018906
- 650 _2
- $a nádory mozku $x mortalita $x patologie $x terapie $7 D001932
- 650 _2
- $a chemoradioterapie $x mortalita $7 D059248
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a difuzní magnetická rezonance $x metody $7 D038524
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a glioblastom $x mortalita $x patologie $x terapie $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počítačové zpracování obrazu $x metody $7 D007091
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a temozolomid $x terapeutické užití $7 D000077204
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vymazal, Josef $u Department of Radiology, Na Homolce Hospital, Roentgenova 2, 150 30, Prague 5, Czech Republic.
- 773 0_
- $w MED00002827 $t Journal of neuro-oncology $x 1573-7373 $g Roč. 146, č. 1 (2020), s. 157-162
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31797235 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125647 $b ABA008
- 999 __
- $a ok $b bmc $g 1595608 $s 1113965
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 146 $c 1 $d 157-162 $e 20191203 $i 1573-7373 $m Journal of neuro-oncology $n J Neurooncol $x MED00002827
- GRA __
- $a NV18-04-00457 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a DRO (NHH, 00023884) IG174301 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20201125